Dr. Babak Navi. Photo credit: @studiobrooke 
Investigators are using the mobile unit as a way to enlist patients for clinical trials in stroke prevention, acute stroke treatment and stroke recovery that are now under way as part of the NIH’s StrokeNet network of 25 regional stroke centers across the country. Weill Cornell Medicine doctors are studying such topics as whether endovascular therapy, which is usually only done within six hours of stroke symptoms, could benefit patients treated between six and 16 hours of onset; and whether a drug typically used to remove excess iron from the body might work to reabsorb blood in the brain after an intracranial hemorrhage. 
Dr. Navi is Weill Cornell Medicine’s site principal investigator for StrokeNet’s POINT (Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke) trial, which aims to determine the safety and efficacy of a combination of low-dose aspirin and another blood-thinning drug in reducing the risk of stroke, heart attack and other complications in patients who have already had a transient ischemic attack (otherwise known as a mini-stroke) or a minor ischemic stroke. “Many of the stroke patients who come in through the mobile unit may be eligible for these trials, so it allows us to identify, recruit and enroll them quicker,” says Dr. Navi. “By studying these interventions, the more likely we are to identify a new treatment that we can provide to the stroke community at large.” 4/4 #stroke #MobileStrokeUnit #CareDiscoverTeach #WeillCornellMedicine
57 likes
  • weillcornellDr. Babak Navi. Photo credit: @studiobrooke
    Investigators are using the mobile unit as a way to enlist patients for clinical trials in stroke prevention, acute stroke treatment and stroke recovery that are now under way as part of the NIH’s StrokeNet network of 25 regional stroke centers across the country. Weill Cornell Medicine doctors are studying such topics as whether endovascular therapy, which is usually only done within six hours of stroke symptoms, could benefit patients treated between six and 16 hours of onset; and whether a drug typically used to remove excess iron from the body might work to reabsorb blood in the brain after an intracranial hemorrhage.
    Dr. Navi is Weill Cornell Medicine’s site principal investigator for StrokeNet’s POINT (Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke) trial, which aims to determine the safety and efficacy of a combination of low-dose aspirin and another blood-thinning drug in reducing the risk of stroke, heart attack and other complications in patients who have already had a transient ischemic attack (otherwise known as a mini-stroke) or a minor ischemic stroke. “Many of the stroke patients who come in through the mobile unit may be eligible for these trials, so it allows us to identify, recruit and enroll them quicker,” says Dr. Navi. “By studying these interventions, the more likely we are to identify a new treatment that we can provide to the stroke community at large.” 4/4 #stroke #MobileStrokeUnit #CareDiscoverTeach #WeillCornellMedicine

Log in to like or comment.